Application Notes:
This product is a glucosylceramide synthase inhibitor, an enzyme that is essential for the synthesis of a very large number of
different glycolipids that are found in many organisms.1 PDMP has four possible isomers due to its two chiral centers (Dthreo,
L-threo, D-erythro, and L-erythro). This product (D,L-threo-PDMP) is a mixture of D-threo (1R,2R) and L-threo
(1S,2S). The D-threo isomer has been shown to be the active glucosyl ceramide synthetase inhibitor.2 However, treatment
with the L-threo isomer has been shown to contribute to an increase in the amount of lactosyl ceramide and may have other
effects as well.3 Due to PDMP’s ability to inhibit the joining of ceramides with carbohydrates there can be an accumulation
of ceramide in the cells and this can lead to apoptosis. This process has been suggested as a treatment for cancer.4 In addition
to its stereochemistry, the acyl chain of PDMP has a very marked effect on the intensity of the inhibitory action of the
molecule. Conduritol beta epoxide (CBE), an inhibitor of beta-glucosidase, and l-phenyl-2-decanoylamino-3-morpholino-lpropanol
(PDMP), an inhibitor of glucosylceramide synthase, can be used to create a model of Gaucher disease and
consequently an accumulation of glucopsychosine.5
References:
1. R. Vunnam, N. Radin, Chem. Phys. Lipids, Vol. 26(3) pp. 265-278, 1980
2. N. Radin et al., Journal of Cellular Physiology, Vol. 141(3) pp. 573-583, 1989
3. J. Inokuchi, S. Usuki and M. Jimbo, J. Biochem., Vol. 117(4) pp. 766-773, 1995
4. N. Radin, et al., Journal of Lipid Research, Vol. 36 pp. 611-621, 1995